Xintian Pharma(SZ:002873)2023-05-15 09:10Group 1: Marketing Strategy and Goals - The company is reforming its marketing system to enhance efficiency and effectiveness, aiming for a significant impact on Q2 performance [2][3] - The marketing reform includes structural adjustments, team building, product and market strategies, brand promotion training, and employee assessment incentives [2][3] - The goal is to increase the revenue share from OTC channels and enhance the company's brand value in women's health management [3] Group 2: Research and Development Initiatives - The company focuses on clinical value in R&D, particularly in gynecology, aligning new product pipelines with existing market resources [3][4] - A comprehensive R&D system has been established, covering the entire process from drug discovery to post-market evaluation [3][4] - There is a commitment to significantly increase R&D expenditure and expand the R&D team to enhance capabilities and efficiency [3][4] Group 3: Financial Performance and Market Positioning - The company aims to create 2-3 major products exceeding 500 million CNY in revenue within the next 3-5 years, alongside multiple products generating over 100 million CNY [4] - The strategy includes expanding coverage in essential drug markets and leveraging leading products to drive market growth [4] - The company anticipates a more stable revenue structure from its main products, supported by a solid foundation from secondary products [4] Group 4: Future Growth and Strategic Investments - The company is preparing for the national market launch of traditional Chinese medicine formula granules, focusing on technological advancement and market strength [5] - Investment in Huylun Pharmaceutical is expected to yield significant positive impacts and enhance the company's strategic positioning in the small molecule drug sector [5] - The company plans to implement a new round of equity incentive plans based on performance targets and growth expectations [5]